TrialJournal of translational medicine2021

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.

Vilde Drageset Haakensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.